Compounded Factors of Lung Cancer Related to Covid-19

Biomark-Diagnostics---November-is-Lung-Cancer-Awareness---3

Compounded Factors of Lung Cancer Related to Covid-19

November is the Lung Cancer Awareness Month. Lung cancer affects both men and women of any race or ethnicity. Every year, 1 out of 3 people diagnosed with cancer dies from lung cancer, which make it the deadliest among all cancer.

But did you know that the compounded links between COVID-19 and Chronic Obstructive Pulmonary Disease or COPD, and Lung Cancer have proven to be devastating to those with the pre-existing conditions?

Share this article with someone you care about.

Share on facebook
Share on twitter
Share on linkedin
Share on reddit
Share on email
Share on whatsapp
Share on telegram
Share on stumbleupon
Share on mix

A COPD Refresher

Chronic Obstructive Pulmonary Disease or COPD is the name given to a set of lung conditions causing breathing difficulties. The first is Emphysema, which causes damage to the air sacs in the lungs. It develops over time, creating gradual damage of the lung tissue and, specifically, the destruction of the lungs’ tiny air sacs, called alveoli. The second is Chronic Bronchitis, which is the consistent, long-term inflammation of the body’s airways.

Over time, COPD makes it increasingly harder for those affected to breathe. Even though medication and lifestyle changes can help manage the symptoms, COPD cannot be reversed through traditional medical technology.

Early warning signs of COPD may include symptoms of shortness of breath, especially when in physical activity. tightness of the chest, wheezing while breathing, chronic coughing producing white, clear, yellow, or green colored mucus, repetitive respiratory infections, unintended weight loss, and an overall lack of energy.

The main cause of COPD is smoking, although the condition can sometimes affect people who have never smoked. The likelihood of developing COPD increases the more you smoke and the longer you’ve smoked. Some cases of COPD are caused by long-term exposure to harmful fumes or dust. Others are the result of a rare genetic problem which means the lungs are more vulnerable to damage1.

COPD as it Relates to Lung Cancer and COVID-19

In 2020, with the onslaught of COVID-19 infections, COPD patients were in a critical danger zone for increased possibility of compounded complications, due to many overlapping risk factors.

As complications are more likely to occur to older patients in both COVID-19 and COPD cases, the risk factors compounded exponentially in patients that are affected by both illnesses.

Recent research shows that both COVID-19 and lung cancer share common symptoms, diagnostic criteria and management. For instance, both are more likely to occur in older people as well in those with underlying medical conditions. Overt Risk factors for COVID-19 include those with lung cancer, COPD, and patients being treated for cancer2.

Patients that are categorized as immunosuppressed are at an additional increased risk factor. The poor lung function in patients with lung cancer may compound and aggravate the negative outcome of COVID-19 in this group. For these reasons, extreme care must be provided in implementing COVID-19 treatments and solutions for these high at-risk groups of patients.

BioMark researchers understand the potential interaction and intersection of lung disease and lung cancer and the likely link to COVID-19. Identification of common key genes and pathways between Covid-19 and lung cancer has been shown by using protein-protein interaction network analysis3.

BioMark Diagnostics – Early-Stage Detection

Early detection is essential to successful treatment and management. The more you know and the earlier you detect potential cancers, the better your chances of survival. Because cancer kills and life expectancy varies dramatically depending on the stage of the cancer and how fast it is caught, at BioMark, we believe that early detection of cancer increases the chance of being cured.

BioMark Diagnostics specializes in early detection of hard to detect and treat cancers through its patented liquid biopsy assays. BioMark Diagnostics’ patented liquid biopsy and metabolomic analysis is a simple and accurate early-stage lung cancer detection solution. Such test is done on a sample of blood to look for cancer biomarkers, or metabolites, from a tumor that are circulating in the blood. A liquid biopsy may be used to help find cancer at an early stage. It may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back.

Share This Article

Cancer is too important to ignore. November is Lung Cancer Awareness Month. Share this article with someone you care about.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Share on whatsapp
WhatsApp
Share on telegram
Telegram
Share on stumbleupon
StumbleUpon
Share on mix
Mix

Sources

Share this post:
Share on facebook
Share on twitter
Share on linkedin
Share on email
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.